- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | NLS and Kadimastem stocks soar following merger agreement | 1 | Pharmaceutical Technology | ||
| Mo | NLS Pharmaceutics und Kadimastem fusionieren in Biotech-Deal | 1 | Investing.com Deutsch | ||
| Mo | NLS Pharmaceutics stock rallies 48% on merger agreement with cell therapy developer Kadimastem | 3 | Seeking Alpha | ||
| Mo | NLS Pharmaceutics AG: NLS Pharmaceutics and Kadimastem Enter into a Definitive Merger Agreement | 217 | ACCESSWIRE | ZURICH, SWITZERLAND and NESS ZIONA, ISRAEL / ACCESSWIRE / November 4, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP) ("NLS"), a biopharmaceutical company, and Kadimastem Ltd. (TASE: KDST.TA") ("Kadimastem")... ► Artikel lesen | |
| 29.07. | Kadimastem To Become Subsidiary Of NLS; Kadimastem Shareholders To Hold 85% Of Merged Company Shares | - | RTTNews | ||
| 29.07. | NLS Pharmaceutics announces binding term sheet to merge with Kadimastem | 2 | Seeking Alpha | ||
| 29.07. | NLS Pharmaceutics AG: NLS Pharmaceutics and Kadimastem Announce Binding Term Sheet to Merge | 312 | ACCESSWIRE | The proposed transaction will create a Nasdaq-traded, biotechnology company with product candidates in advanced stages of clinical development and focused on advancing Kadimastem's allogeneic cell therapy... ► Artikel lesen | |
| 18.07. | Pluri's CDMO to Manufacture Kadimastem's Cell Therapy Candidates | 2 | Contract Pharma | ||
| 18.07. | Pluri Inc.: Pluri's CDMO Selected to Manufacture Kadimastem's Novel Cell Therapy Product Candidates | 673 | GlobeNewswire (Europe) | HAIFA, Israel, July 18, 2024 (GLOBE NEWSWIRE) -- Leading biotechnology company Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) ("Pluri" or the "Company"), which transforms cells into solutions that promote global... ► Artikel lesen | |
| 28.05. | IM Cannabis Corp (3): IM Cannabis terminates term sheet with Kadimastem | 2 | Stockwatch | ||
| 28.05. | IM Cannabis Corp.: IMC announces the termination of a preliminary term sheet with Kadimastem Ltd., a public company traded on the Tel Aviv Stock Exchange to fully focus on the recently legalized German market | 310 | PR Newswire | With Germany delivering accelerated growth after legalization, IMC is keeping all options open to maximize shareholder value
TORONTO and GLIL YAM, Israel, May 28, 2024 /PRNewswire/ --... ► Artikel lesen | |
| 28.02. | IM Cannabis Corp.: IMC Announces Potential Reverse Merger with Kadimastem a leading Clinical cell therapy company | 461 | PR Newswire | Not for distribution to United States newswire services or for dissemination in the United States
TORONTO and GLIL YAM, Israel, Feb. 28, 2024 /PRNewswire/ -- IM Cannabis Corp. (CSE:... ► Artikel lesen |
12 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 8,500 | +4,94 % | Aixtron, Evotec, HelloFresh, Nel ASA, Schalke 04, TUI - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| QIAGEN | 39,940 | -0,57 % | QIAGEN N.V.: QIAGEN erhält FDA-Zulassung für QIAstat-Dx Mini-Panel für eine präzisere ambulante Behandlung von Atemwegserkrankungen | QIAstat-Dx Respiratory Panel Mini erkennt die fünf relevantesten Erreger von Atemwegserkrankungen im ambulanten Bereich und hilft Ärzten dabei, präzise Behandlungsentscheidungen zu treffen // Mithilfe... ► Artikel lesen | |
| ARCELLX | 87,01 | 0,00 % | Arcellx meldet vielversprechende Ergebnisse für Myelom-Behandlung | ||
| ARCUTIS BIOTHERAPEUTICS | 9,300 | +6,65 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | WESTLAKE VILLAGE, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 35,940 | 0,00 % | Edgewise Therapeutics shares maintain price target on positive data | ||
| HARMONY BIOSCIENCES | 33,410 | +1,09 % | Harmony Biosciences Reports Strong Third Quarter 2024 Financial Results And Highlights Catalyst-rich, Late-stage Pipeline Poised To Deliver One Or More New Launches Every Year Over Next Five Years | WAKIX (pitolisant) Net Revenue of $186.0 Million for Third Quarter 2024; Surpassed $2B in Cumulative Net Revenue in Less Than Five Years
On Track to Submit sNDA... ► Artikel lesen | |
| LONGBOARD PHARMACEUTICALS | 59,65 | +0,25 % | Longboard Pharmaceuticals, Inc.: Lundbeck to Acquire Longboard Pharmaceuticals in a Strategic Deal, Significantly Enhancing Its Neuroscience Pipeline | The proposed acquisition represents a significant step forward in Lundbeck's Focused Innovator strategy, adding a highly innovative and complementary product in late-stage development for Developmental... ► Artikel lesen | |
| C4 THERAPEUTICS | 6,090 | 0,00 % | C4 Therapeutics GAAP EPS of -$0.35 beats by $0.05, revenue of $15.36M beats by $10.76M | ||
| BEAM THERAPEUTICS | 23,910 | 0,00 % | Beam Therapeutics Inc. Q3 Loss Misses Estimates | WASHINGTON (dpa-AFX) - Beam Therapeutics Inc. (BEAM) reported Loss for third quarter that missed the Street estimates.The company's earnings came in at -$96.668 million, or -$1.17 per share.... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 22,030 | +2,56 % | Kiniksa Pharmaceuticals, Ltd.: Kiniksa Pharmaceuticals Reports Third Quarter 2024 Financial Results and Recent Portfolio Execution | - ARCALYST® (rilonacept) Q3 2024 net product revenue of $112.2 million, representing 73% year-over-year growth -- ARCALYST 2024 expected net product revenue increased to $410 - $420 million -- Life... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 47,690 | 0,00 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update | KT-621 (STAT6) IND cleared by FDA and dosing in the Phase 1 clinical trial initiated, with data expected in the first half of 2025 Sanofi expanding KT-474/SAR444656 (IRAK4) Phase 2 clinical trials... ► Artikel lesen | |
| ADMA BIOLOGICS | 18,790 | -1,67 % | ADMA Biologics, Inc. (NASDAQ:ADMA) Holdings Increased by Roman Butler Fullerton & Co. | ||
| VIKING THERAPEUTICS | 58,88 | -0,44 % | Novo Nordisk und Eli Lilly aufgepasst: Showdown bei Viking Therapeutics | In der kommenden Handelswoche ist eine hohe Volatilität bei "Adipositas-Aktien" vorprogrammiert. Denn zwischen dem 3. und 6. November steigt die ObesityWeek im texanischen San Antonio. Unter anderem... ► Artikel lesen | |
| BIONTECH | 101,20 | -0,98 % | Biontech-Partner top in Q3: Pfizer übertrifft Erwartungen und hebt Jahresprognose an | © Foto: Foto: Nicolas Maeterlinck/ - BELGA/dpaPfizer hat starke Ergebnisse für das dritte Quartal präsentiert, die sowohl beim Umsatz als auch beim bereinigten Gewinn deutlich über den Analystenschätzungen... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 39,300 | 0,00 % | Structure Therapeutics Inc.: Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek 2024 |
KADIMASTEM LTD gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu KADIMASTEM LTD finden Sie auf Wallstreet Online.
